共 11 条
- [1] A randomized, open-label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (TAC) and mycophenolate mofetil regimen (MMF) in De novo renal allograft recipients: Acute rejection and graft survival results from the orion study[J]. TRANSPLANT INTERNATIONAL, 2007, 20 : 209 - 210Flechner, StuartGlyda, MaciejSteinberg, StevenHarler, Mary Beth
- [2] A randomized, open-label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil (MMF) regimen in de novo renal allograft recipients: Renal function results from the ORION study.[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 440 - 440Flechner, StuartGlyda, MaciejSteinberg, StevenHarler, M. B.
- [3] A randomized, open-label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (TAC) and mycophenolate mofetil (MMF) regimen in de novo renal allograft recipients: Renal function results from the Orion study[J]. TRANSPLANT INTERNATIONAL, 2007, 20 : 25 - 25Flechner, StuartGlyda, MaciejSteinberg, StevenHarler, Mary Beth
- [4] A randomized, open-label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with tacrolimus (TAC) plus mycophenolate mofetil (MMF) in De Novo renal allograft recipients:: Preliminary 2-year safety results from the ORION trial[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 582 - 582Flechner, Stuart M.Cockfield, SandraGrinyo, JosepRuss, GraemeWissing, K. MartinLegendre, ChristopheCopley, J. Brian
- [5] A randomized, open-label study to compare the efficacy and safety of two different sirolimus (SRL) regimens with tacrolimus (TAC) plus mycophenolate mofetil (MMF) in de novo renal allograft recipients: Preliminary 2-year efficacy results from the ORION trial[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 254 - 254Flechner, Stuart M.Cockfield, SandraGrinyo, JosepRuss, GraemeWissing, K. MartinLegendre, ChristopheCopley, J. Brian
- [6] Delayed Graft Function (DGF) in Two Sirolimus (SRL)-Based Regimens Compared with Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) in De Novo Renal Allograft Recipients.[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 277 - 278Flechner, Stuart M.Glyda, MaciejTai, Sandi See
- [7] An open-label pilot study to assess the efficacy and safety of an induction therapy with basiliximab in combination with sirolimus and mycophenolate mofetil in de novo renal allograft recipients.[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 189 - 189Peeters, PVan Vlem, BVan Holder, RLameire, N
- [8] The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study[J]. TRANSPLANT INTERNATIONAL, 2014, 27 (02) : 176 - 186Muehlbacher, FerdinandNeumayer, Hans-Helmutdel Castillo, DomingoStefoni, SergioZygmunt, Anthony J.Budde, Klemens
- [9] Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: Results of a 12-month mulitcentre, open-label, prospective study.[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 191 - 192Vitko, SVogt, BAntoniadis, AKlinger, MKirchher, B
- [10] A phase III, randomized, open-label, comparative, multi-center study to assess the safety and efficacy of Prograf® (Tacrolimus)/MMF, extended release (XL) Tacrolimus/MMF and Neoral® (Cyclosporine)/MMF in de novo kidney transplant recipients:: 2 year results.[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 183 - 183Harold, Yang